[Chart: Jinhe Biotechnology Logo]
Jinhe Biotechnology Co., Ltd.
(No. 71 Xinping Road, Togtoh County, Hohhot, Inner Mongolia Autonomous Region)
2025 Prospectus for Issuance of Shares to Specific Targets via Simplified Procedure
(Draft)
Sponsor (Lead Underwriter)
Ping An Securities
(Address: Floors 22-25, Tower B, Ping An Financial Center, No. 5023 Yitian Road, Futian District, Shenzhen)
July 2026
Statement
-
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the contents of this prospectus, ensuring there are no false records, misleading statements, or major omissions, and assume individual and joint legal liability for any such errors.
-
This prospectus is prepared in accordance with the "Administrative Measures for the Registration of Securities Issuance by Listed Companies," the "Guidelines for Information Disclosure and Format of Companies Offering Securities to the Public No. 61 - Prospectus and Issuance Report for Securities Issued by Listed Companies to Specific Targets," and other requirements.
-
After the completion of this issuance of shares to specific targets via a simplified procedure, the Company is solely responsible for changes in its operations and earnings; investors are solely responsible for investment risks arising from this issuance.
-
This prospectus is the Board of Directors' explanation of this issuance of shares to specific targets via a simplified procedure; any statement to the contrary is a false statement.
-
Investors with any questions should consult their stockbroker, lawyer, professional accountant, or other professional advisor.
-
The matters stated in this prospectus do not represent the approval authority's substantive judgment, confirmation, approval, or registration of the matters related to this issuance.
Important Matters Notice
The Company specifically reminds investors to pay attention to the following major matters or risk factors and to carefully read the relevant chapters of this prospectus. Terms or abbreviations used in this section have the same meanings as those in the "Definitions" section of this prospectus.
-
The Company's 2026 First Quarter Report was disclosed on April 29, 2026. The Company achieved operating income of 741.879 million RMB, a year-on-year increase of 18.67%; net profit attributable to shareholders of the listed company was 62.2971 million RMB, a year-on-year increase of 21.87%; and net profit after deducting non-recurring gains and losses attributable to shareholders of the listed company was 60.0015 million RMB, a year-on-year increase of 22.60%. The 2026 First Quarter Report does not involve any major matters affecting this issuance. The report has been disclosed on the Juchao Information Network (www.cninfo.com.cn); investors are advised to review it.
-
Matters related to this issuance of shares to specific targets via a simplified procedure have been authorized by the Company's 2024 Annual General Meeting and 2025 Annual General Meeting to the Board of Directors, and have been deliberated and approved at the 32nd meeting of the 6th Board of Directors and the 4th meeting of the 7th Board of Directors. According to relevant laws and regulations, this issuance is subject to review and approval by the Shenzhen Stock Exchange and registration by the CSRC before it can be implemented. The final issuance plan shall be subject to the plan approved by the CSRC.